ibudilast has been researched along with ALS - Amyotrophic Lateral Sclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oskarsson, B | 1 |
| Maragakis, N | 1 |
| Bedlack, RS | 1 |
| Goyal, N | 1 |
| Meyer, JA | 1 |
| Genge, A | 1 |
| Bodkin, C | 1 |
| Maiser, S | 1 |
| Staff, N | 1 |
| Zinman, L | 1 |
| Olney, N | 1 |
| Turnbull, J | 1 |
| Brooks, BR | 1 |
| Klonowski, E | 1 |
| Makhay, M | 1 |
| Yasui, S | 1 |
| Matsuda, K | 2 |
| Chen, Y | 1 |
| Wang, H | 1 |
| Ying, Z | 1 |
| Gao, Q | 1 |
| Babu, S | 1 |
| Hightower, BG | 1 |
| Chan, J | 1 |
| Zürcher, NR | 1 |
| Kivisäkk, P | 1 |
| Tseng, CJ | 1 |
| Sanders, DL | 1 |
| Robichaud, A | 1 |
| Banno, H | 1 |
| Evora, A | 1 |
| Ashokkumar, A | 1 |
| Pothier, L | 1 |
| Paganoni, S | 1 |
| Chew, S | 1 |
| Dojillo, J | 1 |
| Gudesblatt, M | 1 |
| Berry, JD | 1 |
| Cudkowicz, ME | 1 |
| Hooker, JM | 1 |
| Atassi, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis[NCT04057898] | Phase 2/Phase 3 | 230 participants (Anticipated) | Interventional | 2020-05-28 | Recruiting | ||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ibudilast and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Neurodegenerative Diseases; Pyridines; Q | 2021 |
2 other studies available for ibudilast and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy.
Topics: Amyotrophic Lateral Sclerosis; Autophagosomes; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Tran | 2020 |
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Humans; Pyridines | 2021 |